Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Inclusion Criteria:

* Pathologically confirmed newly diagnosed Hodgkin lymphoma (HL) meeting one of the following criteria:

  * Classical disease
  * Nodular lymphocyte-predominant disease
* Stage III or IV disease with B symptoms, as defined by ≥ 1 of the following:

  * Unexplained weight loss \> 10% within the past 6 months
  * Unexplained recurrent fever \> 38°C within the past month
  * Recurrent drenching night sweats within the past month
* Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR maximum serum creatinine based on age/gender as follows:

  * 0.4 mg/dL (1 to 5 months)
  * 0.5 mg/dL (6 to 11 months)
  * 0.6 mg/dL (12 to 23 months)
  * 0.8 mg/dL (2 to 5 years)
  * 1 mg/dL (6 to 9 years)
  * 1.2 mg/dL (10 to 12 years)
  * 1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years)
  * 1.7 mg/dL (males) or 1.4 mg/dL (females) (≥ 16 years)
* Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
* AST or ALT \< 2.5 times ULN for age
* Shortening fraction ≥ 27% by ECHO OR ejection fraction ≥ 50% by MUGA (unless due to large mediastinal mass from HL)
* FEV\_1/FVC \> 60% by pulmonary function tests (PFT) (unless due to large mediastinal mass fromHL)

  * For children who are unable to cooperate for PFTs, the criteria are:

    * No evidence of dyspnea at rest
    * No exercise intolerance
    * Pulse oximetry \> 92% on room air
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No pathologic prolongation of QTc interval (\> 450 milliseconds) on 12-lead ECG
* No prior chemotherapy, biological response modifiers (e.g., monoclonal antibody therapy), or radiotherapy
* At least 28 days since prior corticosteroids except for emergent treatment for respiratory distress or spinal cord compression, or for treatment of allergy to contrast agent required for CT scan
* No other concurrent cancer chemotherapy or immunomodulating agents (including steroids)

  * Concurrent corticosteroid therapy as treatment or prophylaxis for anaphylactic reactions allowed
* No concurrent pegfilgrastim